Skip to main content
SpringerLink
Log in

Evidence-Based Management

  • Chapter
  • First Online:
Rosacea

Part of the book series: Updates in Clinical Dermatology ((UCD))

  • 533 Accesses

Abstract

This chapter primarily focuses on the evidence-based management of patients suffering from rosacea. We divide the chapter into topical followed by systemic therapies. Topical therapies include metronidazole, azelaic acid, ivermectin, calcineurin inhibitors, clindamycin, and more. Systemic therapies include tetracyclines, azithromycin, isotretinoin, and antihypertensives. Each individual section references recent literature supporting both positive and negative results. This chapter allows the reader to have a better understanding of different treatment regimens with valid (or quality) evidence to support (or not support) the use of each individual medication.

Dr. Feldman has received research, speaking, and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, AbbVie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and National Psoriasis Foundation. He is the founder and majority owner of www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment.

Dr. Sarah Taylor, Adrian Pona, Sree Kolli, and Abigail Cline have no conflicts to disclose.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Elewski BE, Draelos Z, Dreno B, Jansen T, Layton A, Picardo M. Rosacea – global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol. 2011;25(2):188–200.

    CAS  PubMed  Google Scholar 

  2. Wilkin J, Dahl M, Detmar M, Drake L, Liang MH, Odom R, et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50(6):907–12.

    PubMed  Google Scholar 

  3. Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield L, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis. 2013;92(5):234–40.

    PubMed  Google Scholar 

  4. Reinholz M, Tietze JK, Kilian K, Schaller M, Schofer H, Lehmann P, et al. Rosacea – S1 guideline. J Dtsch Dermatol Ges. 2013;11(8):768–80; −79.

    Google Scholar 

  5. Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part II. Topical and systemic therapies in the treatment of rosacea. J Am Acad Dermatol. 2015;72(5):761–70; quiz 71-2

    PubMed  Google Scholar 

  6. Lautenschlager H. Korneotherapeutische Hautplfege bei Rosacea. Aesthetische Dermatologie. 2010;3:16–20.

    Google Scholar 

  7. Laquieze S, Czernielewski J, Baltas E. Beneficial use of Cetaphil moisturizing cream as part of a daily skin care regimen for individuals with rosacea. J Dermatolog Treat. 2007;18(3):158–62.

    CAS  PubMed  Google Scholar 

  8. Draelos ZD. Facial hygiene and comprehensive management of rosacea. Cutis. 2004;73(3):183–7.

    PubMed  Google Scholar 

  9. Draelos ZD. Cosmetics in acne and rosacea. Semin Cutan Med Surg. 2001;20(3):209–14.

    CAS  PubMed  Google Scholar 

  10. Odom R, Dahl M, Dover J, Draelos Z, Drake L, Macsai M, et al. Standard management options for rosacea, part 2: options according to subtype. Cutis. 2009;84(2):97–104.

    PubMed  Google Scholar 

  11. Abokwidir M, Feldman SR. Rosacea management. Skin Appendage Disord. 2016;2(1–2):26–34.

    PubMed  PubMed Central  Google Scholar 

  12. Jones DA. Rosacea, reactive oxygen species, and azelaic acid. J Clin Aesthet Dermatol. 2009;2(1):26–30.

    PubMed  PubMed Central  Google Scholar 

  13. Weinkle AP, Doktor V, Emer J. Update on the management of rosacea. Clin Cosmet Investig Dermatol. 2015;8:159–77.

    PubMed  PubMed Central  Google Scholar 

  14. Schaller M, Schofer H, Homey B, Hofmann M, Gieler U, Lehmann P, et al. Rosacea management: update on general measures and topical treatment options. J Dtsch Dermatol Ges. 2016;14(Suppl 6):17–27.

    PubMed  Google Scholar 

  15. Nichols K, Desai N, Lebwohl MG. Effective sunscreen ingredients and cutaneous irritation in patients with rosacea. Cutis. 1998;61(6):344–6.

    CAS  PubMed  Google Scholar 

  16. van Zuuren EJ, Fedorowicz Z. Interventions for rosacea: abridged updated Cochrane systematic review including GRADE assessments. Br J Dermatol. 2015;173(3):651–62.

    PubMed  Google Scholar 

  17. Cline A, McGregor SP, Feldman SR. Medical management of facial redness in rosacea. Dermatol Clin. 2018;36(2):151–9.

    CAS  PubMed  Google Scholar 

  18. Narayanan S, Hunerbein A, Getie M, Jackel A, Neubert RH. Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system. J Pharm Pharmacol. 2007;59(8):1125–30.

    CAS  PubMed  Google Scholar 

  19. Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield L, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis. 2013;92(6):277–84.

    PubMed  Google Scholar 

  20. Wolf JE Jr, Del Rosso JQ. The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis. 2007;79(1):73–80.

    PubMed  Google Scholar 

  21. Jorizzo JL, Lebwohl M, Tobey RE. The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial. J Am Acad Dermatol. 1998;39(3):502–4.

    CAS  PubMed  Google Scholar 

  22. Bleicher PA, Charles JH, Sober AJ. Topical metronidazole therapy for rosacea. Arch Dermatol. 1987;123(5):609–14.

    CAS  PubMed  Google Scholar 

  23. Dahl MV, Jarratt M, Kaplan D, Tuley MR, Baker MD. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol. 2001;45(5):723–30.

    CAS  PubMed  Google Scholar 

  24. Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6(6):641–5.

    PubMed  Google Scholar 

  25. Sanchez J, Somolinos AL, Almodovar PI, Webster G, Bradshaw M, Powala C. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol. 2005;53(5):791–7.

    PubMed  Google Scholar 

  26. Dahl MV, Katz HI, Krueger GG, Millikan LE, Odom RB, Parker F, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998;134(6):679–83.

    CAS  PubMed  Google Scholar 

  27. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol. 1999;40(6 Pt 1):961–5.

    CAS  PubMed  Google Scholar 

  28. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139(11):1444–50.

    CAS  PubMed  Google Scholar 

  29. McGregor SP, Alinia H, Snyder A, Tuchayi SM, Fleischer A Jr, Feldman SR. A review of the current modalities for the treatment of papulopustular rosacea. Dermatol Clin. 2018;36(2):135–50.

    CAS  PubMed  Google Scholar 

  30. Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield LF, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis. 2014;93(3):134–8.

    PubMed  Google Scholar 

  31. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48(6):836–45.

    PubMed  Google Scholar 

  32. Draelos ZD, Elewski B, Staedtler G, Havlickova B. Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study. Cutis. 2013;92(6):306–17.

    PubMed  Google Scholar 

  33. Draelos ZD, Elewski BE, Harper JC, Sand M, Staedtler G, Nkulikiyinka R, et al. A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea. Cutis. 2015;96(1):54–61.

    PubMed  Google Scholar 

  34. Thiboutot DM, Fleischer AB, Del Rosso JQ, Rich P. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol. 2009;8(7):639–48.

    PubMed  Google Scholar 

  35. Del Rosso JQ, Bruce S, Jarratt M, Menter A, Staedtler G. Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. J Drugs Dermatol. 2010;9(6):607–13.

    PubMed  Google Scholar 

  36. Coda AB, Hata T, Miller J, Audish D, Kotol P, Two A, et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol. 2013;69(4):570–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Thiboutot DM, Fleischer AB Jr, Del Rosso JQ, Graupe K. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol. 2008;7(6):541–6.

    PubMed  Google Scholar 

  38. Wolf JE Jr, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis. 2006;77(4 Suppl):3–11.

    PubMed  Google Scholar 

  39. Draelos ZD. The rationale for advancing the formulation of azelaic acid vehicles. Cutis. 2006;77(2 Suppl):7–11.

    PubMed  Google Scholar 

  40. Sauder D, Miller R, Gratton D, Danby W, Griffiths C, Phillips S. The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study. J Dermatol Treat. 1997;8:79–85.

    Google Scholar 

  41. Torok HM, Webster G, Dunlap FE, Egan N, Jarratt M, Stewart D. Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis. 2005;75(6):357–63.

    PubMed  Google Scholar 

  42. Kim MB, Kim GW, Park HJ, Kim HS, Chin HW, Kim SH, et al. Pimecrolimus 1% cream for the treatment of rosacea. J Dermatol. 2011;38(12):1135–9.

    CAS  PubMed  Google Scholar 

  43. Bamford JT, Elliott BA, Haller IV. Tacrolimus effect on rosacea. J Am Acad Dermatol. 2004;50(1):107–8.

    PubMed  Google Scholar 

  44. Weissenbacher S, Merkl J, Hildebrandt B, Wollenberg A, Braeutigam M, Ring J, et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. Br J Dermatol. 2007;156(4):728–32.

    CAS  PubMed  Google Scholar 

  45. Karabulut AA, Izol Serel B, Eksioglu HM. A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea. J Eur Acad Dermatol Venereol. 2008;22(6):729–34.

    CAS  PubMed  Google Scholar 

  46. Koca R, Altinyazar HC, Ankarali H, Muhtar S, Tekin NS, Cinar S. A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. Clin Exp Dermatol. 2010;35(3):251–6.

    CAS  PubMed  Google Scholar 

  47. Rompel R, Petres J. Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg. 2000;26(7):638–43.

    CAS  PubMed  Google Scholar 

  48. Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol. 2003;17(5):493–503.

    CAS  PubMed  Google Scholar 

  49. El-Heis S, Buckley DA. Rosacea-like eruption due to topical pimecrolimus. Dermatol Online J. 2015;21(5).

    Google Scholar 

  50. Layton A, Thiboutot D. Emerging therapies in rosacea. J Am Acad Dermatol. 2013;69(6 Suppl 1):S57–65.

    CAS  PubMed  Google Scholar 

  51. Aquilina C, Viraben R, Sire S. Ivermectin-responsive Demodex infestation during human immunodeficiency virus infection. A case report and literature review. Dermatology. 2002;205(4):394–7.

    CAS  PubMed  Google Scholar 

  52. Forstinger C, Kittler H, Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol. 1999;41(5 Pt 1):775–7.

    CAS  PubMed  Google Scholar 

  53. Stein L, Kircik L, Fowler J, Tan J, Draelos Z, Fleischer A, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13(3):316–23.

    PubMed  Google Scholar 

  54. Taieb A, Ortonne JP, Ruzicka T, Roszkiewicz J, Berth-Jones J, Peirone MH, et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015;172(4):1103–10.

    CAS  PubMed  Google Scholar 

  55. Taieb A, Khemis A, Ruzicka T, Baranska-Rybak W, Berth-Jones J, Schauber J, et al. Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study. J Eur Acad Dermatol Venereol. 2016;30(5):829–36.

    CAS  PubMed  Google Scholar 

  56. Raoufinejad K, Mansouri P, Rajabi M, Naraghi Z, Jebraeili R. Efficacy and safety of permethrin 5% topical gel vs. placebo for rosacea: a double-blind randomized controlled clinical trial. J Eur Acad Dermatol Venereol. 2016;30(12):2105–17.

    CAS  PubMed  Google Scholar 

  57. Kocak M, Yagli S, Vahapoglu G, Eksioglu M. Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study. Dermatology. 2002;205(3):265–70.

    CAS  PubMed  Google Scholar 

  58. Bikowski JB, Del Rosso JQ. Demodex dermatitis: a retrospective analysis of clinical diagnosis and successful treatment with topical crotamiton. J Clin Aesthet Dermatol. 2009;2(1):20–5.

    PubMed  PubMed Central  Google Scholar 

  59. Abokwidir M, Fleischer AB. An emerging treatment: topical ivermectin for papulopustular rosacea. J Dermatolog Treat. 2015;26(4):379–80.

    CAS  PubMed  Google Scholar 

  60. Stein Gold L, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z, et al. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol. 2014;13(11):1380–6.

    PubMed  Google Scholar 

  61. Breneman D, Savin R, VandePol C, Vamvakias G, Levy S, Leyden J. Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol. 2004;43(5):381–7.

    CAS  PubMed  Google Scholar 

  62. Chang AL, Alora-Palli M, Lima XT, Chang TC, Cheng C, Chung CM, et al. A randomized, double-blind, placebo-controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks. J Drugs Dermatol. 2012;11(3):333–9.

    CAS  PubMed  Google Scholar 

  63. Freeman SA, Moon SD, Spencer JM. Clindamycin phosphate 1.2% and tretinoin 0.025% gel for rosacea: summary of a placebo-controlled, double-blind trial. J Drugs Dermatol. 2012;11(12):1410–4.

    CAS  PubMed  Google Scholar 

  64. Wilkin JK, DeWitt S. Treatment of rosacea: topical clindamycin versus oral tetracycline. Int J Dermatol. 1993;32(1):65–7.

    CAS  PubMed  Google Scholar 

  65. Steinhoff M, Buddenkotte J, Aubert J, Sulk M, Novak P, Schwab VD, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15(1):2–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Altinyazar HC, Koca R, Tekin NS, Esturk E. Adapalene vs. metronidazole gel for the treatment of rosacea. Int J Dermatol. 2005;44(3):252–5.

    CAS  PubMed  Google Scholar 

  67. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130(3):319–24.

    CAS  PubMed  Google Scholar 

  68. Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield LF, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. Cutis. 2014;93(1):18–28.

    PubMed  Google Scholar 

  69. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed. 2003;2(4):234–45.

    PubMed  Google Scholar 

  70. Del Rosso JQ, Webster GF, Jackson M, Rendon M, Rich P, Torok H, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56(5):791–802.

    PubMed  Google Scholar 

  71. Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol. 1966;78(12):649–52.

    CAS  PubMed  Google Scholar 

  72. Jackson JM, Kircik LH, Lorenz DJ. Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea. J Drugs Dermatol. 2013;12(3):292–8.

    CAS  PubMed  Google Scholar 

  73. van der Linden MMD, van Ratingen AR, van Rappard DC, Nieuwenburg SA, Spuls PI. DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety. Br J Dermatol. 2017;176(6):1465–74.

    PubMed  Google Scholar 

  74. van Zuuren EJ, Kramer SF, Carter BR, Graber MA, Fedorowicz Z. Effective and evidence-based management strategies for rosacea: summary of a Cochrane systematic review. Br J Dermatol. 2011;165(4):760–81.

    PubMed  Google Scholar 

  75. Mrowietz U, Kedem TH, Keynan R, Eini M, Tamarkin D, Rom D, et al. A phase II, randomized, double-blind clinical study evaluating the safety, tolerability, and efficacy of a topical minocycline foam, FMX103, for the treatment of facial papulopustular rosacea. Am J Clin Dermatol. 2018;19(3):427–36.

    PubMed  Google Scholar 

  76. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008;7(6):573–6.

    PubMed  Google Scholar 

  77. Del Rosso JQ. Anti-inflammatory dose doxycycline in the treatment of rosacea. J Drugs Dermatol. 2009;8(7):664–8.

    PubMed  Google Scholar 

  78. Baldwin HE. Systemic therapy for rosacea. Skin Therapy Lett. 2007;12(2):1–5, 9

    CAS  PubMed  Google Scholar 

  79. Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol. 2008;47(3):284–8.

    CAS  PubMed  Google Scholar 

  80. Bakar O, Demircay Z, Gurbuz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol. 2004;43(2):151–4.

    CAS  PubMed  Google Scholar 

  81. Elewski BE. A novel treatment for acne vulgaris and rosacea. J Eur Acad Dermatol Venereol. 2000;14(5):423–4.

    CAS  PubMed  Google Scholar 

  82. Lova Navarro M, Sanchez-Pedreno Guillen P, Victoria Martinez AM, Martinez Menchon T, Corbalan Velez R, Frias IJ. Papulopustular rosacea: response to treatment with oral azithromycin. Actas Dermosifiliogr. 2018;109(6):529–35.

    CAS  PubMed  Google Scholar 

  83. Hsu CC, Lee JY. Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective beta-adrenergic blocker. J Am Acad Dermatol. 2012;67(3):491–3.

    PubMed  Google Scholar 

  84. Park JM, Mun JH, Song M, Kim HS, Kim BS, Kim MB, et al. Propranolol, doxycycline and combination therapy for the treatment of rosacea. J Dermatol. 2015;42(1):64–9.

    CAS  PubMed  Google Scholar 

  85. Schaller M, Almeida LM, Bewley A, Cribier B, Dlova NC, Kautz G, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176(2):465–71.

    CAS  PubMed  Google Scholar 

  86. Rallis E, Korfitis C. Isotretinoin for the treatment of granulomatous rosacea: case report and review of the literature. J Cutan Med Surg. 2012;16(6):438–41.

    PubMed  Google Scholar 

  87. Park H, Del Rosso JQ. Use of oral isotretinoin in the management of rosacea. J Clin Aesthet Dermatol. 2011;4(9):54–61.

    PubMed  PubMed Central  Google Scholar 

  88. Irvine CKP, Marks R. Isotretinoin in the treatment of rosacea and rhinophyma. London: Martin Dunitz.

    Google Scholar 

  89. Gollnick H, Blume-Peytavi U, Szabo EL, Meyer KG, Hauptmann P, Popp G, et al. Systemic isotretinoin in the treatment of rosacea – doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges. 2010;8(7):505–15.

    PubMed  Google Scholar 

  90. Bostanci O, Borelli C, Schaller M. Treatment of extrafacial rosacea with low-dose isotretinoin. Acta Derm Venereol. 2010;90(4):409–10.

    PubMed  Google Scholar 

  91. Jansen T, Plewig G. Clinical and histological variants of rhinophyma, including nonsurgical treatment modalities. Facial Plast Surg. 1998;14(4):241–53.

    CAS  PubMed  Google Scholar 

  92. Hoting E, Paul E, Plewig G. Treatment of rosacea with isotretinoin. Int J Dermatol. 1986;25(10):660–3.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, USA

    Adrian Pona, Abigail Cline & Sree S. Kolli

  2. Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, USA

    Sarah L. Taylor

  3. Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Steven R. Feldman

  4. Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Steven R. Feldman

  5. Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Steven R. Feldman

Authors
  1. Adrian Pona
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abigail Cline
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sree S. Kolli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sarah L. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Steven R. Feldman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adrian Pona .

Editor information

Editors and Affiliations

  1. Louisiana State University, New Orleans, LA, USA

    John Havens Cary

  2. Dermatology Clinic, University of California San Francisco, San Francisco, CA, USA

    Howard I. Maibach

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pona, A., Cline, A., Kolli, S.S., Taylor, S.L., Feldman, S.R. (2020). Evidence-Based Management. In: Cary, J.H., Maibach, H.I. (eds) Rosacea. Updates in Clinical Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-030-52097-7_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-52097-7_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-52096-0

  • Online ISBN: 978-3-030-52097-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation